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Abstract
The propensity to develop an anxiety disorder is thought to be determined by genetic and environmental factors. Here we
investigated the relationship between a genetic predisposition to trait anxiety and experience-based learned fear in a
psychopathological mouse model. Male CD-1 mice selectively bred for either high (HAB), or normal (NAB) anxiety-related
behaviour on the elevated plus maze were subjected to classical fear conditioning. During conditioning both mouse lines
showed increased fear responses as assessed by freezing behaviour. However, 24 h later, HAB mice displayed more
pronounced conditioned responses to both a contextual or cued stimulus when compared with NAB mice. Interestingly, 6 h
and already 1 h after fear conditioning, freezing levels were high in HAB mice but not in NAB mice. These results suggest
that trait anxiety determines stronger fear memory and/or a weaker ability to inhibit fear responses in the HAB line. The
enhanced fear response of HAB mice was attenuated by treatment with either the a2,3,5-subunit selective benzodiazepine
partial agonist L-838,417, corticosterone or the selective neurokinin-1 receptor antagonist L-822,429. Overall, the HAB
mouse line may represent an interesting model (i) for identifying biological factors underlying misguided conditioned fear
responses and (ii) for studying novel anxiolytic pharmacotherapies for patients with fear-associated disorders, including
post-traumatic stress disorder and phobias.
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Introduction
Fear is a phasic, apprehensive arousal to an explicit threat of an
aversive stimulus dissociable from a long-term state of anxiety [1].
Fear and anxiety are part of a universal survival strategy ensuring
adaptive responses to a threat, returning to baseline activity once it
has passed [2]. In some individuals, though not all, the experience
of an aversive situation that elicits extreme fear may cause a
prolonged and/or inappropriate response which even persists after
withdrawal of the stimulus. Such subjects develop a pathological
form of anxiety including post-traumatic stress disorder (PTSD) or
phobia [3,4,5]. What it is that determines either resilience or the
propensity to developing an anxiety disorder is thought to result
from a combination of biological factors that are heritable and
diverse learning experiences gained in early life [6,7]. For
example, trait anxiety is considered to be a major risk factor for
anxiety disorders [8] as well as depression [9].
Fear and anxiety have some parallels as they seem to be
genetically linked ([10,11,12,13,14]; but see [15,16]), and also as
they share common neurocircuitries and brain areas, including the
prefrontal cortex, the hippocampus and the amygdala (e.g. for
review see [1,17,18,19]). In addition, the same pharmacotherapies,
including the prototypical anxiolytics benzodiazepines (BZD), are
effective in patients suffering from diverse forms of anxiety
disorders, whether or not they are the result of conditioning
processes [20,21,22].
Regarding pathological anxiety, some of the major challenges in
neuroscience involve developing tools for the identification of
vulnerable subjects, preventing the onset of an anxiety disorder
and, once it is established, discovering the best treatment targets
and strategies. The present study was therefore aimed at clarifying
the impact of high innate anxiety on experience-based learned fear
by characterizing contextual and cued conditioned fear responses
in two mouse lines selectively bred for either high (HAB) or normal
(NAB) anxiety-related behaviour [23]. These paradigms differen-
tially involving the amygdala and hippocampus in animals and
humans [24,25] were chosen because conditioning processes occur
in the aetiology of many anxiety disorders, including phobias and
PTSD [26,27]. Furthermore, we investigated whether any of the
following treatments were able to reduce high conditioned fear
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822,429, a selective neurokinin-1 (NK1) receptor antagonist
[28,29], corticosterone (CORT), which has been shown to inhibit
the retrieval of particularly emotionally arousing information
[30,31,32], and the a2,3,5-subunit selective BZD partial agonist L-
838,417 [33].
Results
Flinch/jump test
No differences were revealed between HAB (n=4) and NAB
(n=4) mice in their threshold for flinching (HAB: 0.3360.01 mA;
NAB: 0.2860.03 mA; U6,8=20.624, p=0.686), jumping (HAB:
0.4960.02 mA; NAB: 0.4460.03 mA; U4.5,8=21.042, p=0.343)
or vocalizing (HAB: 0.6060.02 mA; NAB: 0.5260.02 mA;
U2.5,8=21.648, p=0.114) indicating that foot shocks with
0.7 mA were sufficient to induce aversive responses in both lines
and, thus, may be applied as unconditioned stimulus (US) for fear
conditioning.
Fear conditioning
When animals were placed into the conditioning chamber for
fear conditioning (Figures 1A and 2A) or into an empty mouse
cage for cued fear expression (Figures 2B and D), the freezing
behaviour was negligible in both HAB and NAB lines (,3%)
indicating that there was no contextual fear component in cued
auditory fear expression. No statistically significant difference
between lines in baseline freezing to both contexts was observed.
Contextual fear conditioning. Upon repeated US presen-
tations conditioned responses as indicated by freezing behaviour
increased to the same extent in both the HAB and NAB lines
(pairing effect: F4,68=53.482, p,0.001; line effect: F1,17=0.439,
p=0.516; line x pairing interaction: F4,68=0.304, p=0.874),
reaching a maximum of approximately 54% freezing (Figure 1A).
24 h later, when animals were re-exposed to the conditioning
context for 3 min, freezing levels were elevated in HAB mice
compared with NAB mice (t=3.793, df=17, p=0.002; Figure 1B).
Compared with the period post the last US presentation on the
conditioning day, freezing levels were reduced in NAB mice
(t=3.637, df=8, p=0.007) during fear expression, but not in
HAB mice (t=0.672, df=9, p=0.518; Figure 1B).
Cued fear conditioning. Irrespective of whether condi-
tioning was performed during the light phase or the dark phase
of the cycle, both HAB and NAB mice acquired cued conditioned
fear as indicated by an increase in freezing levels of up to 50–60%
within five pairings of a 2-min tone (conditioned stimulus; CS) co-
terminating with the US (pairing effect during light phase:
F4,72=75.011, p,0.001; during dark phase: F4,52=31.657,
p,0.001; Figures 2A and 2C). Two-way ANOVA with repeated
measures revealed no significant line effect (light phase:
F1,18=0.955, p=0.342; dark phase: F1,13=0.676, p=0.426) or
line x pairing interaction (light phase: F4,72=0.345, p=0.847; dark
phase: F4,52=0.230, p=0.883) during either the light or the dark
phase. 24 h later, expression of cued conditioned fear by
presenting 3 CSs was tested in animals of both lines. HAB mice
differed greatly from NAB mice in their fear responses to the CS
during both the light phase (t=8.851, df=18, p,0.001; Figure 2B)
and the dark phase (t=3.938, df=13, p=0.002; Figure 2D) of the
cycle, with HAB mice displaying more pronounced freezing levels
than NAB mice. While NAB mice showed significantly lower
freezing levels during the fear-expression test than during the last
CS-US pairing of the conditioning session (light phase: t=6.091,
df=10, p,0.001; dark phase: t=3.588, df=6, p=0.012; Figure 2),
freezing levels between these two testing periods were found
similar in HAB mice (light phase: t=0.674, df=8, p=0.520; dark
phase: t=1.850, df=7, p=0.107; Figure 2). The circadian cycle
did not affect the percentages of freezing displayed by the two lines
at the end of the fear conditioning (line effect: F1,31=1.616,
p=0.213; line x pairing x cycle interaction: F4,124=0.355,
p=0.840) or during fear expression (line effect: F1,31=0.701,
p=0.409; line x cycle interaction: F1,31=0.841, p=0.366). During
the dark phase unconditioned HAB and NAB mice (i.e. exposed to
the CS without receiving any CS-US pairing) displayed very low
freezing levels in response to the CS at the end of the fear
conditioning (HAB: 0.2460.24%; NAB: 0%) as well as during the
fear-expression test (HAB: 0.9360.34%; NAB: 0.6260.30%).
Conditioned and unconditioned animals differed significantly in
fear responses during both sessions (pairing x CS interaction
during fear conditioning: F4,112=28.085, p,0.001; line x CS
interaction during fear expression: F1,27=16.250, p,0.001).
In all experiments performed to investigate short-term recall of
cued conditioned fear, HAB and NAB animals were conditioned
within five CS-US pairings to the same extent (data not shown).
As with the 24 h period, expression of cued conditioned fear
differed greatly between HAB and NAB mice 1 h (t=15.220,
df=12, p,0.001) and 6 h (t=12.825, df=12, p,0.001) after the
fear conditioning (Figure 3). There was no significant effect of
testing period on fear-expression levels (F2,42=2.475, p=0.096;
Figure 3).
Pharmacological modulation of learned cued fear in HAB
mice. Next we tested the possibility to attenuate the higher fear
expression of HAB mice by pharmacotherapeutic interventions
using either the a2,3,5-subunit selective BZD partial agonist L-
838,417, CORT or the selective NK1 receptor antagonist L-
822,429. Indeed, all three treatments were effective, though to a
different extent (Figure 4). Compared with vehicle treatment,
acute application of L-838,417 caused a reduction in freezing
levels of 20% in HAB mice (t=3.275, df=13, p=0.006;
Figure 4A). Similarly, HAB mice pre-treated with CORT
displayed 20% lower freezing levels than vehicle-treated controls
(t=2.893, df=17, p,0.010; Figure 4B) while the NK1 receptor
antagonist L-822,429 reduced freezing levels by 26% (t=4.055,
df=18, p,0.001; Figure 4C). In addition, HAB mice chronically
Figure 1. Contextual conditioned fear in HAB and NAB mice.
Although freezing behaviour (assessed during each 2-min period post
US presentation) increased in HAB and NAB animals in response to 5 US
presentations to the same extent (A), indicating comparable fear
conditioning of both lines, HAB mice displayed significantly higher fear
responses than NAB mice when exposed to the conditioning context
for 3 min 24 h later (B). Data are presented as means 6 SEM. n=9 per
line. **p,0.01 HAB vs. NAB,
11p,0.01 fear expression vs. last US
presentation.
doi:10.1371/journal.pone.0016849.g001
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displayed 40% less freezing compared with untreated HAB mice
(t=6.194, df=13, p,0.001; Figure 4D). However, chronic
treatment with the NK1 receptor antagonist did not affect cued
fear conditioning (treatment effect: F1,12=1.055, p=0.325;
treatment x pairing interaction: F4,48=2.020, p=0.107). The
distance travelled, monitored during the first 2-min habituation
period before the onset of the CS in HAB mice was not affected by
acute treatment with either L-838,417 (vehicle: 436649 cm; drug:
307657 cm; t=1.699, df=13, p=0.113), CORT (vehicle:
498688 cm; drug: 415655 cm; t=0.817, df=17, p=0.425), or
L-822,429 (vehicle: 552685 cm; drug: 397677 cm; t=1.357,
df=18, p=0.192).
Discussion
Using classical Pavlovian fear-conditioning paradigms, we have
demonstrated that a mouse line characterized by extremely high
innate anxiety-related behaviour (HAB) expressed more contex-
tual- and cue-dependent fear relative to NAB controls. In addition,
we have shown for the first time that the high level of fear
responses exhibited by HAB animals could be reduced by
treatment with either the subtype selective BZD agonist L-
838,417, the NK1 receptor antagonist L-822,429, or CORT.
There have been various attempts to link learned fear with
innate anxiety as a vulnerability factor for the development of
anxiety disorders using behaviourally selected rodents or recom-
binant strains, including the Roman Low-Avoidance rats [11,12],
low open arm rats [34], high fear reactivity rats [10], mice selected
for high levels of fear conditioning [13], and recombinant inbred
mice [15]. In these models stronger fear conditioning coincides
with an increased level of fear expression. On the other hand, fear
conditioning and fear expression are not altered in HAB rats [35],
or in low fear recovery rats [10], whereas the extinction of their
learned (cued) fear memories is impaired; an investigation of
extinction of learned fear in the HAB and NAB lines, however,
was not within the scope of the present study, although a parallel
study (Yen et al., submitted) does examine this issue.
In contrast to these previously described models [10,11,13,
15,34,35], we report here similar behavioural responses during
fear conditioning, but different fear expression in response to the
CS by the HAB and NAB lines. The finding of similar fear
conditioning in HAB and NAB mice using the present protocol
Figure 2. Cued conditioned fear in HAB and NAB mice during the light (A, B) and dark (C, D) phases of the circadian cycle. Both lines
showed the same increasing conditioned responses to the CS-US presentations, as indicated by freezing levels during CS presentation (A, C). In
contrast, compared with NAB mice, HAB mice showed more pronounced freezing levels in response to the CS only during fear expression performed
24 h later (B, D). Note that freezing levels prior CS presentation (pre-CS) were negligible indicating that there was no contextual fear component (B,
D). Data are presented as means 6 SEM. n=7–11 per line. **p,0.01, ***p,0.001 HAB vs. NAB;
1p,0.05,
111p,0.001 fear expression vs. last CS-US
pairing.
doi:10.1371/journal.pone.0016849.g002
Figure 3. Short- and long-term recall of cued conditioned fear
in HAB and NAB mice. CS only was presented to separate HAB and
NAB groups 1 h, 6 h (short-term) or 24 h (long-term) after cued fear
conditioning. Irrespective of consolidation period, HAB mice showed
pronounced freezing during the fear expression test, but not NAB mice.
Data are presented as means 6 SEM. n=6–8 per experimental group.
***p,0.001 HAB vs. NAB.
doi:10.1371/journal.pone.0016849.g003
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result in altered CS-US association in HAB mice. A similar
observation in humans displaying individual differences in trait
anxiety levels supports this result [36]. It remains to be tested
whether HAB and NAB mice would differ in fear acquisition when
using a weaker conditioning protocol, such as applying a foot
shock just above the flinching threshold (e.g. 0.35 mA).
During fear conditioning, final freezing levels of up to 50% were
reached in HAB and NAB mice. Interestingly, the freezing levels
we observed in NAB mice at the end of the conditioning session
are higher than those previously reported in the CD-1 strain,
which range between 2% [37] and 40% [38] freezing. At this stage
it has to be emphasized that NAB mice do not represent a normal
cohort of CD-1 mice in terms of variability in inborn anxiety, as
the selective breeding for mice spending approximately 35% of
their time on the open arm of an elevated plus maze [23,39]
resulted in the clustering of an anxiety-related phenotype around
the strain mean rather than around the whole anxiety spectrum
typical of outbred CD-1 mice [40]. Accordingly, it may well be
that in NAB mice fear responses gathered around the mean
freezing levels usually displayed by CD-1 mice during fear
conditioning. Indeed, when we used the present paradigm on
unselected CD-1 mice purchased from a commercial supplier
instead of NAB mice, we observed mean freezing levels of
approximately 50%, with individual freezing levels ranging from
2% to 80% at the end of the conditioning session (data
unpublished).
24 h after fear conditioning animals were tested for their ability
to express learned fear. NAB mice showed little freezing behaviour
(around 15%), irrespective of whether the CS was a cue or the
context. The low freezing levels of NAB mice during fear
expression are comparable to those of unselected CD-1 mice
observed at the laboratory of our collaborator (Yen et al.,
submitted) and at our laboratory (data unpublished), as well as
to those levels reported previously [37,38,41]. These data suggest
that NAB mice show normal, strain (CD-1)-specific fear expression
24 h after fear conditioning. In contrast to NAB mice, HAB mice
displayed pronounced freezing responses to the CS suggesting that
a high anxiety trait may trigger increased fear expression. This
increased fear expression of HAB mice may be caused either by an
increased inability to inhibit fear responses, which has also been
described in humans [42], or by building a stronger fear memory.
Both ideas reflect psychopathology of enhanced fear.
In order to investigate whether short-term memory of
conditioned fear is perturbed in HAB mice, we subjected mice
of both lines to fear-expression tests within a few hours following
cued fear acquisition. While HAB mice always displayed
pronounced fear responses to the CS that were similar to the
24 h fear expression, the amount of freezing was significantly
reduced in NAB mice 6 h and already 1 h after fear conditioning.
This indicates low retention in the memory of the CS-US
association following conditioning using the present protocol.
However, since conditioned fear expression remains high in CD-1
mice when a much more aversive (1063 mA foot shock)
conditioning protocol is applied [43], it may be further speculated
that NAB mice would require stronger fear conditioning for better
association of the CS-US.
Since locomotion is reduced in novel environments, but not in
the home cage [23,44] in HAB mice compared with NAB mice, it
might be argued that the observed differences in freezing levels in
response to a CS may simply reflect altered activity between the
two lines. This, however, is unlikely for several reasons. First, when
Figure 4. Pharmacological modulation of learned cued fear in HAB mice. An acute application of either the a2,3,5-subunit selective
benzodiazepine partial agonist L-838,417 (1 mg/kg; A), corticosterone (CORT; 10 mg/kg; B) or the selective NK1 receptor antagonist L-822,429
(30 mg/kg; C) 30 min prior to testing reduced fear expression as indicated by the percentage of freezing displayed by HAB mice during fear
expression. Chronic treatment with L-822,429 (30 mg/kg/day; D) attenuated CS-induced freezing levels even more. Data are presented as means 6
SEM. n=7–10 per experimental group.
##p,0.01,
###p,0.001 drug vs. vehicle.
doi:10.1371/journal.pone.0016849.g004
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they showed hardly any freezing behaviour prior presentation of the
first US, indicating that the testing contexts per se did not elicit fear
responses and, importantly, these low freezing levels did not differ
between the two lines. Second, unconditioned animals from both
lines did not show any freezing in response to the CS; and third, in
both HAB and NAB mice freezing levels increased at a similar rate
reaching the same maximum level during fear conditioning.
On the other hand, there is evidence that stress responses are
related to an inborn sensitivity to anxiety and pain [45,46]. For
example, there is a high overlap between brain circuitries mediating
stress, anxiety and nociception, including those involving the
amygdala, the hypothalamus and the neocortex [47,48]. Interest-
ingly, pain sensitivity is altered in patients with high levels of anxiety
or PTSD (e.g. [49,50,51,52,53]). Despite a proposed dissociation
between pain sensitivity and conditioned emotional responses to
pain in normal rats [54], it may be speculated that the differences
that exist between HAB and NAB mice in terms of fear-memory
consolidation are secondary to their differences in sensitivity to the
US. In order to investigate this idea, animals were subjected to a
flinch/jump test. It was found that the two lines did not differ in
terms ofthe thresholdofshockperception asindicated byflinchesor
jumps expressing emotionally driven reactions in response to the
foot shock [55], which suggests that enhanced fear expression in
HAB mice is not driven by an altered pain perception upon US
exposure. Similar to the HAB mouse line, baseline mechanical pain
sensitivity has also been found to be unaltered in HAB rats [56].
Although selective breeding for innate anxiety did not coincide with
a selection for innate aversion to painful stimuli at the sensorimotor
level (shock reactivity), the possibility cannot be excluded, that
differences in the processing and storage of the shock response in
HAB mice compared with NAB mice may have contributed to their
altered fear memories.
We were further stimulated by studies showing that the
circadian clock, known to regulate locomotor activity and arousal
of the central nervous system, may also affect learning and
memory [41,57,58]. Moreover, since there is evidence that
hippocampal long-term potentiation, which is a neuronal correlate
of learning and memory, is greater and more stable during the
night than it is during the daytime [59,60], we performed fear-
conditioning experiments during the night cycle, when both lines
are highly active (data not shown). Again, both HAB and NAB
mice acquired cued conditioned fear responses to the same extent,
while 24 h later, fear expression was more pronounced in HAB
mice compared to NAB mice. Freezing levels in response to the
CS were comparable between the light and dark phases, indicating
that the circadian cycle did not influence fear responses in either
line using the described protocol. Thus, it is suggested that fear
conditioning in HAB and NAB mice is robust and independent of
the activity phase it is tested in. Hence, testing of the fear-reducing
potential of compounds in HAB mice (see below) can be reliably
performed during daytime, when their inactive phase coincides
with general business hours.
Finally, we investigated whether it was possible to attenuate the
increased conditioned fear responses of HAB mice by pharmaco-
logical interventions. NAB animals were not included into this set
of experiments as their fear expression was already very low (see
Figures 1 and 2) and, thus, reproducible fear-reducing effects of
drugs would have been difficult to detect limiting the additional
pharmacological information gained. At first, we tested the effect
of the a2,3,5-subunit selective BZD partial agonist L-838,417 on
fear expression in the HAB line since the attenuation of anxious
states by compounds acting at the BZD binding site of the GABA-
A receptor is well established both experimentally [18] and
clinically [30,32,61]. L-838,417, thought to be non-sedative
compared with other clinically effective BZDs [62], indeed
reduced fear expression in HAB mice. At this stage it should be
mentioned that we cannot completely rule out a slight sedative
effect of the drug in HAB mice, as indicated by a lesser, yet
statistically insignificant, effect in terms of the distance travelled
during the phase before CS onset, compared with vehicle-treated
controls. However, concerning the most important (i.e. fear
reducing) effect of the drug, a potential sedative drug effect would
have rather increased freezing levels, which is opposed to the
reduction we observed in HAB mice. Possible sedative effects of L-
838,417 will be investigated in follow up studies using a range of
drug doses and different behavioural tests. To our knowledge, this
is the first study demonstrating a reduction of enhanced
conditioned fear responses in a psychopathological mouse model
of trait anxiety through use of this drug. Furthermore, we have
provided the first evidence of pharmacological sensitivity of adult
HAB mice to an established class of anxiolytics, the BZDs.
In addition to BZDs, both the NK1 receptor antagonist L-
822,429 and CORT suppressed the freezing behaviour displayed
by HAB mice during the fear-expression test, with L-822,429
being the most effective. The fear-reducing effect of L-822,429
could be enhanced by chronic treatment. Anxiolytic effects of
NK1 receptor antagonists have been demonstrated in rodents and
humans after both acute and chronic treatments [28,63,64].
Besides, NK1 receptor antagonists are promnestic [65] rendering
it unlikely that chronic treatment with L-822,429 impaired fear
learning. Indeed, chronic treatment with the NK1 receptor
antagonist did not affect fear conditioning in HAB animals per
se, further suggesting that fear conditioning and expression of
learned fear represent two distinct processes, most likely only the
latter involving the NK1 receptor system. The fear-reducing
effects of CORT in HAB subjects can be explained by its ability to
inhibit the recall of previously acquired, emotionally arousing
information [66,67,68,69,70,71] – an ability that has so far been
demonstrated in ‘‘normal’’ animals [72,73,74,75] and in humans
with PTSD or phobias [30,32,61]. This effect is opposite of the
evidence for an acute anxiogenic effect of CORT in tests of
anxiety [76]. The fact that CORT and diverse NK1 receptor
antagonists are currently in various stages of clinical trials
concerned with the treatment of anxiety disorders [28,31,77,78]
underlines a potential translational value to the present results in
HAB mice.
Using an experimental paradigm of learned fear in combination
with mice selectively bred for either high or normal anxiety-related
behaviour, these findings demonstrate an association between
innate anxiety and enhanced fear expression. Furthermore, it was
shown that the enhanced fear expression in HAB mice could be
attenuated by a BZD, a well established anxiolytic class of drugs,
as well as by CORT and a NK1 receptor antagonist, which are
currently under clinical trials for the treatment of specific anxiety
disorders. Thus, the HAB mouse may be a particularly powerful
model for the functional analysis of neuroanatomical networks,
candidate genes and gene products underlying susceptibility to
learned emotionality [79,80], and for the development of novel,
improved pharmacotherapies for patients with fear-associated
disorders, including PTSD and phobias.
Materials and Methods
Ethics statement
All experiments performed were approved by the Austrian
Ethical Committee on Animal Care and Use (Bundesministerium
fu ¨r Bildung, Wissenschaft und Kultur, Austria; approval ID:
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laws and policies with the aim of minimizing animal suffering and
reducing the number of animals needed.
Animals
Experiments were carried out on adult male HAB (n=113) and
NAB mice (n=46) at 12–15 weeks of age bred in the animal
facilities of the Department of Pharmacology and Toxicology,
University of Innsbruck, Austria. As previously described in more
detail [23], the two lines were derived from a Swiss CD-1 outbred
population selectively inbred for either high or normal anxiety-
related behaviour displayed on the elevated plus maze, with HAB
mice spending less than 15% of the testing time on its open arms,
compared with approximately 25–35% for NAB mice with no
overlapping between the lines. The behavioural phenotype of each
mouse was confirmed by an elevated plus maze test at 7 weeks of
age. Animals were group housed (up to four litter mates per cage),
and supplied with pelleted food and water ad libitum under
standard laboratory conditions (12 h light/dark cycle with lights
on at 7:00, 2261uC, 60% humidity).
Fear conditioning
Behavioural experiments were carried out either during the
light phase (8:00–15:00) or the dark phase (20:00–3:00) of the cycle
as indicated below. All paradigms consisted of both a fear-
conditioning session and a fear-expression test at different post
conditioning intervals, i.e. presenting the CS to the animals for a
short duration.
Contextual fear conditioning. Contextual fear conditioning
was performed in a fully automated fear-conditioning system
(TSE, Technical & Scientific Equipment GmbH, Bad Homburg,
Germany) consisting of a Perspex arena (23623635 cm) and a
metal grid floor. For conditioning, mice were placed into the
brightly illuminated (300 lux) context and five unsignalled mild
foot shocks (0.7 mA, 2 s; US) were delivered. 2-min stimulus-free
periods preceded, separated, and followed the US presentations.
24 h after the fear conditioning, mice were returned to the same
context for 3 min to assess fear expression. The arena was
thoroughly cleaned with tap water between each animal.
Cued auditory fearconditioning. Cued fear conditioning was
performed according to a protocol described previously [81]. On day
1, HAB and NAB mice received five pairings (inter-trial interval
2 min) of a tone (white noise, 80 dB, 2 min; CS) with a co-
terminating mild foot shock (0.7 mA, 2 s; US) in a clean standard
conditioning chamber (26630632 cm; Coulbourn Instruments,
Allentown, PA, USA) under bright illumination (300 lux). In order
to control for unspecific behavioural responses to the CS, separate
groups of each line were presented with the CS only, never paired
with the US. 24 h later (day2),mice wereplaced in a standardempty
mouse cage (26620613 cm, swiped with ethanol) with a smooth
surface and illuminated by dim red light, where 3 CS separated by 5-s
intervals were presented. In addition, fear expression was also tested
1 h and 6 h after the conditioning in separate groups of animals. In
all sessions, animals were given 2-min stimulus-free periods prior to
and post last stimulus exposure. Stimulus presentation was controlled
by the Habitest operant system (Coulbourn Instruments, Allentown,
USA). Foot shocks were delivered via an interface to the metal grid of
the conditioning chamber, and auditory stimuli were applied via a
speaker (Coulbourn Instruments, Allentown, PA, USA) installed
above the contexts.
Behavioural analysis. All sessions were recorded via
individual video cameras mounted above each context. Freezing
behaviour, defined as the absence of all non-respiratory movements
[82,83], was taken as the measure of fear and was scored by an
experienced investigator blinded to mouse lines and treatments. In
contextual fear-conditioning experiments percentages of freezing
time for each mouse were calculated during each 2-min period post
US presentation in the conditioning and during the 3-min context
exposure in the fear expression tests while percentages of freezing
time for each mouse were calculated during each CS presented in
conditioning and during 3 CSs in fear expression sessions in cued
auditory fear-conditioning experiments.
Drug treatments
Acute treatments. The a2,3,5-subunit selective BZD partial
agonist L-838,417 (1 mg/kg; kindly donated by Merck) was
suspended in a 0.5% methylcellulose solution (Sigma). CORT
(10 mg/kg; Sigma-Aldrich) was dissolved in a 45% cyclodextrine
solution (Sigma). The non-peptidergic, brain-penetrating NK1
receptor antagonist L-822,429 [2-cyclopropoxy-5-(5-(trifluoromethyl)
tetrazol-1-yl)benzyl]-(2-phenyl-piperidin-3-yl)amine (30 mg/kg), syn-
thesized in house with high affinity to the rat and mouse NK1
receptor [29] was dissolved in saline. Drugs were administered intra-
peritoneally to HAB mice 30 min prior to the fear-expression test.
Control animals received vehicle only.
Chronic treatment. The NK1 receptor antagonist L-
822,429 was chronically applied to HAB mice via the drinking
water for three weeks. A drug intake of approximately 30 mg/kg/
day was achieved by adapting the concentrations of the NK1
receptor antagonist in the drinking solutions according to mean
drinking volume and body weight per cage. Control HAB mice
were supplied with pure tap water.
Flinch/jump test
Since high freezing levels have been only described in
unselected CD-1 mice when foot shocks with high amperages
were used [43], separate HAB and NAB groups were tested in the
flinch/jump test. Animals were individually placed in standard
conditioning boxes (see above). After 2 min of habituation to the
chamber, animals were subjected to 1 s shocks of gradually
increasing amperage (0.05 mA every 30 s) starting from 0.05 mA.
Mice were scored for their first visible response to the shock
(flinch), their first pronounced motor response (run or jump), and
their first vocalized distress, as previously described [84].
Data presentation and statistics
Data represent mean 6 standard error of the mean (SEM).
Statistical analysis was performed using STATISTICA 7.1 (Stat
Soft, Inc., USA). First, all data were tested for homoscedasticity
using Levene’s test. Since a non-parametric distribution was
revealed for behavioural measures in the flinch/jump test, data
were statistically analyzed using a Mann-Whitney U test. All other
data followed a parametric distribution, and thus were further
analyzed using a multiple-way ANOVA with repeated measures
followed by a Bonferroni test, where allowed. Significant
differences in the fear expression test were analyzed using a
Student’s t-test.
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